New research by Monash University has found that taking daily low-dose aspirin will not reduce long-term cancer risk in older adults and may be associated with a higher risk of cancer-related death. The findings, published in the JAMA Oncology journal, challenges findings from an ongoing ‘Aspree’ (ASPirin in Reducing Events in the Elderly) study that suggested aspirin reduced cancer risk after about a decade of use, particularly for colorectal cancer. During the original Aspree trial, participants were randomly assigned to receive either 100 mg of aspirin daily or a matched placebo. In the subsequent observational phase, participants stopped taking the study medication. Researchers then assessed the association between aspirin use and cancer outcomes across both phases.